Clinical trials for a potential multiple sclerosis (MS) treatment have begun.
Compound BGC20-0134 was developed by the University of Greenwich in association with Kings College London and the trials will be conducted by life sciences company BTG.
The new treatment is thought to work by encouraging MS patients' immune system to "rebalance" itself - preventing the inflammation of the brain which leads to the neurological disorder.
Initial tests of the medication showed promising results, with patients suffering from the relapsing-remitting form of MS experiencing some clinical benefits, including decreases in relapse rates, disability and pain.
Louise Makin, BTG's chief executive officer, says: "The effective treatment of multiple sclerosis remains a significant unmet need.
"We are pleased to have started clinical development of BGC20-0134, which has the potential to address different forms of the disease and has the advantage of being an oral product."
According to the MS Society, the illness affects some 85,000 people in the UK.
Please click here for advice about how to find the right type of care.